Business Wire

KAYTUS

14.5.2024 09:01:36 CEST | Business Wire | Press release

Share
KAYTUS Released MotusAI, an AI Development Platform for Highly Efficient GPU Resource Scheduling and Task Orchestration

KAYTUS, a leading IT infrastructure provider, has unveiled MotusAI, an AI development platform now accessible for trial worldwide. MotusAI is tailored for deep learning and AI development, integrating GPU and data resources alongside AI development environments to streamline computing resource allocation, task orchestration, and centralized management. It accelerates training data and manages AI model development workflows seamlessly. This platform drastically reduces resource investment, boosts development efficiency, elevates cluster computing power utilization to over 70%, and significantly enhance in large-scale training task scheduling performance.

Streamline AI Development for Cost-Effectiveness and Efficiency

The rapid expansion of enterprise AI business and AI model development brings forth challenges including low computing efficiency, complexity in model development, varied requirements for task orchestration across different scenarios, and unstable computing resources. Ensuring efficient, flexible, and stable operation of AI business is critical for enterprises to consistently derive business insights, generate revenue, and maintain competitiveness.

Optimize Resource Management for Maximum Computing Power

MotusAI efficiently allocates resources and workloads by implementing intelligent and flexible GPU scheduling. It caters to diverse AI workload demands for computing power by dynamically allocating GPU resources based on demand. With multi-dimensional and dynamic GPU resource allocation, including fine-grained GPU scheduling and support for Multi-Instance GPU (MIG), MotusAI effectively meets computing power requirements across various scenarios such as model development, debugging, and training.

Streamline Task Orchestration for Versatile Support of Various Scenario

MotusAI has revolutionized cloud-native scheduling systems. Its scheduler surpasses the community version by dramatically improving the scheduling performance of large-scale POD tasks. MotusAI achieves rapid startup and environment readiness for hundreds of PODs, boasting a five times increase in throughput and a five times decrease in latency compared to the community scheduler. This ensures efficient scheduling and utilization of computing resources for large-scale training. Moreover, MotusAI enables dynamic scaling of AI workloads for both training and inference services, supporting burst tasks and fulfilling diverse scheduling needs across various scenarios.

MotusAI empowers users to maximize computing resources, spanning from fine-grained division of single-card multiple instances to large-scale parallel computing across multiple machines and cards. By integrating features like computing power pooling, dynamic scaling, and GPU single-card reuse, MotusAI significantly enhances computing power utilization, achieving an average utilization rate of over 70%. Furthermore, it enhances computing efficiency by leveraging cluster topology awareness and optimizing network communication.

Data Transfer Acceleration for Three Times Efficiency Improvement

MotusAI excels in data transfer acceleration through innovative features such as supporting local loading and computing of remote data, which eliminates delays caused by network I/O during computation. Utilizing strategies like "zero-copy" data transfer, multi-threaded retrieval, incremental data updates, and affinity scheduling, MotusAI significantly reduces data caching cycles. These enhancements greatly improve AI development and training efficiency, resulting in 2-3 times boost in model efficiency during data training.

Reliable, and Automatically Fault-Tolerant Platform

MotusAI supports performance monitoring and alerts for computing resources, providing real-time status updates for core platform services. It employs sandbox isolation mechanisms for data with higher security levels. In case of resource failures or abnormalities, MotusAI automatically initiates fault tolerance processes to ensure the quickest possible recovery during interrupted training tasks. This approach reduces fault handling time by over 90%, on average.

Comprehensive Management of AI Model Development in One Integrated Solution

MotusAI accelerates AI development and supports every stage of large model development. From managing data samples and software stacks to designing model architectures, debugging code, training models, tuning parameters, and conducting evaluation testing, MotusAI offers a complete platform. It integrates popular development frameworks like PyTorch and TensorFlow, along with distributed training frameworks such as Megatron and DeepSpeed.

Moreover, MotusAI enables comprehensive lifecycle management of AI inferencing services, including offline and online testing, A/B testing, rolling release, service orchestration, and service decommissioning. These features collectively enhance the business value of AI technology, fostering continuous business growth.

Additionally, MotusAI provides an integrated visual management and operation interface that covers computing, networking, storage, and application resources. Operational staff can comprehensively manage, monitor, and evaluate the overall platform operation status through a single interface.

Free Trial Available

MotusAI is now available worldwide for a trial period, offering free remote access for one month, along with testing, training, and support. Users can also opt for local deployment using their own devices and environment, with local deployment testing support from KAYTUS. For more information1 and to register2, please visit Link1, Link2.

About KAYTUS

KAYTUS is a premier provider of IT infrastructure products and solutions, delivering a suite of cutting-edge, open, and environmentally friendly infrastructure solutions for cloud, AI, edge computing, and other emerging technologies. With a customer-centric approach, KAYTUS adapts flexibly to user needs through its agile business model. Learn more at KAYTUS.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240513665403/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release

SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag

Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release

Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a

Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release

Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op

GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release

GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc

Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release

Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye